公开(公告)号：US20230346789A1

公开(公告)日：2023-11-02

申请号：US18193958

申请日：2023-03-31

Applicant: MSD International GmbH ,  MSD International Business GmbH ,  Servier Pharmaceuticals LLC.

Inventor： Patrick WEN ,  Tim CLOUGHESY ,  Islam HASSAN

IPC: A61K31/53 ,  A61K39/395

CPC classification number: A61K31/53 ,  A61K39/3955

Abstract: Provided are methods for treating enhancing brain tumors in patients in need thereof using a combination of an inhibitor of mutant IDH1/2 enzyme and an anti PD-1 agent.

公开(公告)号：US11730748B2

公开(公告)日：2023-08-22

申请号：US17103391

申请日：2020-11-24

Applicant: MSD International GMBH

Inventor： Cyril B. Dousson ,  David Dukhan ,  Christophe C. Parsy ,  Stephane L. Bogen

IPC: A61K31/675 ,  A61P1/16 ,  A61P31/12 ,  C07F9/6558 ,  C07F9/6561

CPC classification number: A61K31/675 ,  A61P1/16 ,  C07F9/65586 ,  C07F9/65616

Abstract: The present invention relates to Compounds of Formula (I) or Formula (II):




or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

公开(公告)号：US11605025B2

公开(公告)日：2023-03-14

申请号：US16874232

申请日：2020-05-14

Applicant: MSD International GmbH ,  MSD Czech Republic s.r.o.

Inventor： Yingqi Peh ,  Kah Hin Chin ,  Shao Ying Choo ,  Sucitro Dwijayana Sidharta ,  Richard Dobis

IPC: G06N20/00 ,  G06F17/18

Abstract: As a data science project goes into the production stage, model maintenance to maintain model quality and predictive accuracy becomes a concern. Manual model maintenance by data scientists can become a time- and labor-intensive process, especially for large scale data science projects. An early warning system addresses this by performing systematic statistical and algorithmic checks for prediction accuracy, stability, and model assumption validity. A diagnostic report is generated that helps data scientists to assess the health of the model and identify sources of error as needed. Well-performing models can be automatically deployed without further human intervention while poor performing models trigger a warning or alert to the data scientists for further investigation and may be removed from production until the performance issues are addressed.

公开(公告)号：US20230036592A1

公开(公告)日：2023-02-02

申请号：US17830817

申请日：2022-06-02

Applicant: Surface Oncology, Inc. ,  MSD International GmbH

Inventor： Alison O'NEILL ,  Jou-Ku CHUNG ,  Robert ROSS ,  Andrew LAKE

IPC: C07K16/40 ,  A61P35/00 ,  C07K16/30

Abstract: The invention provides methods and uses of treating cancer with and IgG4 anti-CD39_229p antibody in combination with pembrolizumab, wherein the IgG4 anti-CD39_229p antibody is provided at particular doses and dosages.

公开(公告)号：US20210324081A1

公开(公告)日：2021-10-21

申请号：US17287358

申请日：2019-10-21

Applicant: GlaxoSmithkline Intellectual Property Development Limited ,  MSD International GmbH

Inventor： Elaine Marie PAUL ,  Patrick MAYES ,  Catherine E. ELLIS ,  Jessica KATZ

IPC: C07K16/28 ,  A61K9/00 ,  A61P35/00 ,  A61K39/395

Abstract: The present invention relates to a method of treating cancer comprising administering to the human an ICOS binding protein or antigen binding portion thereof at a dose of about 0.08 mg to about 240 mg and administering to the human a PD1 antagonist.

公开(公告)号：US20210205339A1

公开(公告)日：2021-07-08

申请号：US17103391

申请日：2020-11-24

Applicant: MSD International GMBH

Inventor： Cyril B. Dousson ,  David Dukhan ,  Christophe C. Parsy ,  Stephane L. Bogen

IPC: A61K31/675 ,  A61P1/16 ,  C07F9/6558 ,  C07F9/6561

Abstract: The present invention relates to Compounds of Formula (I) or Formula (II): or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

公开(公告)号：US20250052757A1

公开(公告)日：2025-02-13

申请号：US18799733

申请日：2024-08-09

Applicant: Vaccinex, Inc. ,  MSD International GmbH

Inventor： Elizabeth EVANS ,  Maurice ZAUDERER ,  Terry FISHER

IPC: G01N33/574 ,  A61K31/675 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  G01N33/68

Abstract: The disclosure relates to methods for treating cancer or selecting subjects for cancer treatment using low PD-L1 expression as a patient biomarker prior to treatment.

公开(公告)号：US20250034211A1

公开(公告)日：2025-01-30

申请号：US18712016

申请日：2022-11-23

Applicant: Merck Sharp & Dohme LLC ,  MSD International GmbH ,  Agency for Science, Technology and Research

Inventor： Hubert Josien ,  Arun Chandramohan ,  Charles William Johannes ,  Christopher J. Brown ,  Srinivasaraghavan Kannan ,  Anthony William Partridge ,  Chandra Shekhar Verma ,  Lin Yan ,  Tsz Ying Yuen

IPC: C07K7/56 ,  A61K38/00 ,  A61K45/06 ,  A61P35/00

Abstract: The crosslinked peptidomimetic macrocycles disclosed herein comprise an alkene or alkyne staple and a poly-amino acid C-terminal tail. These crosslinked peptidomimetic macrocycles have improved binding to MDM2 and MDMX (aka MDM4), are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX thereby antagonizing MDM2 and MDMX binding to p53. These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.

公开(公告)号：US20240354929A1

公开(公告)日：2024-10-24

申请号：US18638678

申请日：2024-04-18

Applicant: Merck Sharp & Dohme LLC ,  MSD International GmbH

Inventor： Nitin Kaul ,  Guglielmo Iozzia

IPC: G06T7/00 ,  G06V10/774 ,  G06V10/776 ,  G06V20/70

CPC classification number: G06T7/0004 ,  G06V10/774 ,  G06V10/776 ,  G06V20/70 ,  G06T2207/20081

Abstract: A method or a system for automated product inspection. The system receives multiple images of products captured from various perspectives. For each image, a machine-learning model is applied to the image to identify one or more defects in the products. Responsive to detecting a defect of a type, the system labels the image with the detected type of defect. The system further identifies duplicate defects based in part on data associated with context of the detected defects and data associated with context of cameras that captured images with the identified defects. The system groups duplicate defects together and initiates a corrective action based on the grouped defects.

公开(公告)号：US20220409724A1

公开(公告)日：2022-12-29

申请号：US17772468

申请日：2020-10-28

Applicant: Eisai R&D Management Co., Ltd. ,  Merck Sharp & Dohme Corp. ,  MSD International GmbH

Inventor： Yoichi OZAWA ,  Yasuhiro FUNAHASHI ,  Yu KATO

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/47 ,  A61K31/53

Abstract: The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.